Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Spinal Cord Trauma Treatment Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”
LOS ANGELES, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The Global Spinal Cord Trauma Treatment Market is expected to grow at a CAGR of around 3.6% from 2020 to 2027 and reach the market value of over US$ 4,547.2 Mn by 2027.
North America takes a strong lead in the spinal cord trauma treatment market. Factors responsible for the growth of regional market involve high incidences of spinal cord injuries (SCI) and a large number of people traveling to the US for SCI treatment. Such factors contribute fullest for the growth of regional market. Well established trauma centers, methods to assess the autonomic nerve functions in the patients, and emergency medical tests are the factors that contribute fullest for the regional growth. It is well supported by the American Spinal Injury Association (ASIA) and Autonomic Standards Classification. Such support by the governing bodies and quick response towards treatment fuels the North American regional growth for spinal cord trauma treatment market.
Download Sample Pages Of This Report@ https://www.acumenresearchandconsulting.com/request-sample/2444
Additionally, development of rehabilitation centers assist patients to recover from spinal cord injuries. Well established rehabilitation centers with equipped rehab teams and therapies further spur the regional growth in North America. Rehab programs are a conglomeration of physical therapies and skill building activities. Moreover, counseling to provide social and emotional support. The rehab team led by the doctors is highly specialized in physical medicine and often involves social workers, physical and occupational therapist, recreational therapists, and others.
High investment and development alternative treatment options to improve patient condition are the prominent factors for the growth of European market for spinal cord trauma treatment market. However, currently used treatment modalities in Europe have limited therapeutic impact for improvement of patient condition suffering from spinal cord trauma. European Spinal Cord Injury Federation (ESCIF) released that there is still no cure, therapy, or treatment for (chronic) spinal cord injury. Through rising number of ongoing and planned clinical trial it has achieved a certain level of recovery by alternative treatment. This alternative treatment involves stem cells & combination regeneration/repair strategies, scar and growth inhibitors reduction & regeneration/repair combination strategies, electrical stimulation of the spinal cord, transcranial stimulation (TMS), brain-machine-interface (BMI), and unproven/commercial therapies.
View Table Of Content Of This Report@ https://www.acumenresearchandconsulting.com/spinal-cord-trauma-treatment-market
Key Takeaway
In November 2019, BioArctic AB announced results of an interim analysis of Phase 1/2 study of its new product SC0806 in patients with complete spinal cord injury. The results show that patient’s positive response towards drug was measured by electric impulses that was passed through the injured area for treatment.
Segmental Analysis
Spinal cord trauma treatment market is treatment type, injury type, and end-user.
By treatment type, the market is segmented as corticosteroid, spinal traction, and surgery. By injury, the market is bifurcated into partial spinal cord injury and complete spinal cord injury. By end-user, the market is classified into trauma centers and hospitals.
By treatment type, surgery is the leading segment in the spinal cord trauma treatment market globally. With more than 85% revenue share, surgery segment by treatment type will lead the market globally for spinal cord trauma treatment during the forecast period. Surgery segment is expected to register a CAGR of 3.5% during the forecast period. On the other hand, corticosteroid is anticipated to be the second most lucrative segment in the global spinal cord trauma treatment market globally.
Some of the leading competitors are Asterias Biotherapeutics, BioArctic AB, ReNetX Bio., BioTime, Inc., Kringle Pharma, Inc., and InVivo Therapeutics., and among others.
Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports
Some of the key observations regarding Spinal Cord Trauma Treatment industry include:
- In October 2018, InVivo Therapeutics announced joint research agreement with Q Therapeutics, Inc., a privately held developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury. The research collaboration focuses upon the evaluation of InVivo's proprietary PLGA-PLL based Neuro-Spinal Scaffold with Q Therapeutics adult neural progenitor cells. This involves induced pluripotent stem cells (iPSCs). The two companies will share the respective technologies to explore the potential pre-clinical safety, feasibility, ad synergistic properties of the combined technologies for application in the CNS.
- In June 2019, ReNetX Bio, Inc. announced that the USFDA has allowed the company's investigational new drug (IND) application for its leading drug candidate, fusion protein AXER-204. Studies show that ReNetX's proprietary therapeutic AXER-204 resulted in significant re-growth of nerve fibers and increase functionality involving axonal regeneration, axonal sprouting, and synaptic plasticity.
Inquiry Before Buying@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2444
Buy This Premium Research Report – https://www.acumenresearchandconsulting.com/buy-now/0/2444
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
For Latest Update Follow Us:
https://www.facebook.com/acumenresearchandconsulting
https://www.linkedin.com/company/acumen-research-and-consulting